Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
ConditionObesity
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorIHU Strasbourg
About this trial
EGO-Trial is the first multicenter study in France which aims to evaluate the efficacy of Endoscopic Sleeve Gastroplasty (ESG) in patients with obesity. This project fills a critical national gap by providing real-world, multicentric data from diverse French healthcare settings, offering insight into the safety, efficacy, and variability of ESG practices across institutions
The project is expected to generate robust, multicentric clinical evidence on the safety and efficacy of ESG in patients with obesity within the French healthcare context.
Eligibility criteria
Qualifiers
Patients aged 18 to 75 years.
Patients with a Body Mass Index (BMI) ≥ 30 kg/m².
Patients who have failed non-surgical weight loss interventions (diet, exercise, pharmacological therapy).
Patients not eligible for bariatric surgery or does not wish to undergo it.
Disqualifiers
Patients with contraindications to endoscopic gastroplasty
Patients with active peptic ulcer disease or significant gastroparesis
Patients with a history of bariatric, gastric, or esophageal surgery.
Patients who have started medication in the last 3 months that is known to cause weight gain.
Trial design
Treatments tested in this trial
- Endoscopic sleeve gastroplasty
Treatment groups
300 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov